

## State of Oklahoma SoonerCare Enhertu<sup>®</sup> (Fam-Trastuzumab Deruxtecan-nxki) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Information	on
Physician billing (HCPCS code:	) Start Date (	(or date of next dose):
Dose:Regimen:		n:
Billing Provider Information		
Provider NPI: Provider Name:		
Provider Phone:	Provider Phone: Provider Fax:	
Prescriber Information		
Prescriber NPI: Prescriber Name:		
Prescriber Phone:	Prescriber Fax:	Specialty:
Criteria		
For Initial Authorization:		
1. Please indicate the diagnosis a	nd information:	
☐ Breast Cancer		
A. Is diagnosis unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive		
breast cancer? Yes_	No	
B. Has member received 2 or more prior anti-HER2-based regimens in the metastatic setting?		
Yes No		
☐ Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma		
A. Is disease locally advanced or metastatic? Yes No		
B. Is disease HER2-positive? Yes No		
C. Has member received at least 1 prior trastuzumab-based regimen? Yes No		
☐ If diagnosis is not listed above, please indicate diagnosis:		
Additional Information:		
For Continued Authorization:		
Date of last dose:		
<ol> <li>Does member have any evidence of progressive disease while on fam-trastuzumab deruxtecan therapy?</li> </ol>		
Yes No		
3. Has member experienced any adverse drug reactions related to fam-trastuzumab deruxtecan therapy?		
Yes No		
	tions:	
Prescriber Signature: Date: I certify that the indicated treatment is medically necessary and all information is true and correct to the		
best of my knowledge.	•	

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this

form in full will result in processing delays.

## PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

## **CONFIDENTIALITY NOTICE**

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.